COVID-Era Telemedicine Flexibilities for Controlled Substances – Again
For the fourth time since the onset of the COVID-19 pandemic, the federal government has extended temporary rules allowing healthcare providers to prescribe certain controlled substances via telemedicine without an in-person examination. The latest extension, signaled by a White House budget posting titled “Fourth Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications,” keeps the regulatory status quo in place through at least 2026.
What’s Being Extended?
Originally enacted by the Drug Enforcement Administration (DEA) in March 2020, these flexibilities permit remote initiation of prescriptions for Schedule II and Schedule III medications.
Without this waiver, the Ryan Haight Online Pharmacy Consumer Protection Act of 2008 would generally require an in-person exam before prescribing controlled substances.
Despite years of temporary relief, no permanent telemedicine prescribing framework has been finalized. After years of potential new, permanent (and likely restrictive) rules, none have come to fruition and the temporary rule has been extended. While this means status quo for many providers (namely, telehealth providers in the wellness and longevity sector), it continues the shakiness of many business models relying solely on these rules to operate in “compliance”.
Regardless of the Federal rule, clinics must also be aware of state specific telehealth and prescribing laws, which can track or conflict with Federal laws.
Legal and Policy Questions Ahead
Several unresolved issues loom:
- Should Schedule II and Schedule III drugs be regulated differently in telemedicine?
- How should ADHD stimulants—increasingly prescribed via telehealth platforms—be overseen to prevent misuse?
Industry Impact
The prolonged uncertainty has fueled a boom in telemedicine startups built around remote prescribing of schedule II medications (hormones, ADHD medications and buprenorphine). Critics warn of heightened risks of diversion and overprescribing, though some studies show no elevated rates of misuse among telehealth patients compared to in-person cohorts.
Looking Forward
This fourth extension buys time but not permanence. Telemedicine providers, patients, and regulators remain in limbo. The Trump administration now holds the pen on whether to codify broad flexibilities, tighten oversight, or chart a middle path.
At OLKM, we can guide your practice through the regulatory web of telehealth prescribing.
